Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“If I understand your post you are concerned with your (IGg Kappa) light chains increase so soon after your ASCT for multiple myeloma. Consider…”
Dear Cancer Coach- I was diagnosed with Multiple Myeloma in 2015. I underwent 4 rounds of VRd for my induction therapy. I followed this with an autologous stem cell transplant. My MM is IGg kappa. When the transplant was complete and out 100 days my light chains were 21. The Dr. thought that might just a mistake. I was put on 10 mg revlimid 21 day maintenance and Zometa once a month in July of 2016 and things have been going well until this month when we discovered the light chains have risen to 38. Would be interested in the coaching information please. Mary
Dear Mary- I am sorry to read of your MM diagnosis. If I understand your post you are concerned that your light chains have increased so soon post ASCT. Two things for you to consider.
First of all, according to this article linked below, published recently (2/17), there is no relationship between overall survival and outcome post ASCT. Yes, all MMers want to reach complete remission after an ASCT but there is no actual research that confirms the benefit of CR.
Secondly, as the other article linked below explains, freelight chains can be a little out of the normal range and not be a problem or what some call a “biological relapse.”
If you are interested in working on your MM together I will get more specific info from you such as any genetic abnormalities you may have. Also, I will encourage you to consult with a MM specialist. Nothing against your current oncologist, I am simply thinking that another perspective might be helpful in your case. I can provide the names and emails of specialists for you to consider.
I will email you separately the MM CC pdf that outlines the myeloma cancer coaching program. In addition I will include the guide that outlines integrative therapies for both Revlimid and Dex.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Your challenge will be to identify and undergo those chemotherapy regimens that address your specific issues. At the same time I will present evidence-based, non-toxic MM therapies.
“There was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in patients with newly diagnosed multiple myeloma, according to the results of a meta-regression analysis published recently in the European Journal of Hematology…
“Meta-regression analyses failed to demonstrate any association between CR or (CR or VGPR) with either overall survival or progression-free survival both in patients receiving autologous stem cell transplant [ASCT] and in non-ASCT patients…”
Similarly, an analysis of trials of patient who did not undergo transplant showed no correlation of progression-free survival with CR or with combined CR and VGPR.
“The lack of association between response rates and hard clinical outcomes raises concerns about fast track approval of new drugs, based on results from trials utilizing solely these surrogate markers,” the researchers wrote. “Given the limitations of CR or VGPR to accurately reflect survival in patients with newly diagnosed multiple myeloma, prospective studies should include MRD in addition to conventional response outcomes.”
“If your free light chains (FLC) are slightly out of range, have you come out of remission? If you are experiencing no symptoms and all other diagnostic markers are within the normal range then what do you do? More importantly, when does a multiple myeloma (MM) patient decide he or she has relapsed and should undergo more toxicity?
The second study linked and excerpted below raises the issue of MM patients who may be in remission yet have one or more free light chain markers out of the normal range. As a MM survivor who is often out of normal ranges on tests large and small, I think it is normal to be out of the normal range sometimes. I think MMers should try to balance the damage caused by their MM with the damage caused by the toxicity of therapy…”
